Copyright
©The Author(s) 2021.
World J Clin Oncol. Aug 24, 2021; 12(8): 675-687
Published online Aug 24, 2021. doi: 10.5306/wjco.v12.i8.675
Published online Aug 24, 2021. doi: 10.5306/wjco.v12.i8.675
Table 1 Characteristics of the 95 patients with sentinel lymph nodes with macrometastases
Characteristics | n = 95 | % |
Age (range), yr | 51.9 (23-82) | - |
Average tumor size, mm | 17.4 | - |
Tumor size | ||
0-10 | 14 | 14.7 |
11-15 | 25 | 26.3 |
16-20 | 26 | 27.4 |
21-30 | 18 | 18.9 |
31-40 | 6 | 6.3 |
> 50 | 1 | 1.1 |
In situ | 5 | 5.3 |
Menopausal status | ||
Pre | 50 | 52.6 |
Post | 45 | 47.4 |
Histology type | ||
Ductal | 76 | 80 |
Lobular | 15 | 15.8 |
Others | 4 | 4.2 |
Phenotype | ||
Luminal | 83 | 87.4 |
Basal | 9 | 9.5 |
Her-2 | 3 | 3.2 |
Grade | ||
I | 16 | 16.8 |
II | 54 | 56.8 |
I + II | 70 | 73.7 |
III | 24 | 25.3 |
Unknown | 1 | 1.1 |
Surgery | ||
Conservative | 63 | 66.3 |
Mastectomy | 32 | 33.7 |
Number of SN removed | ||
1 | 35 | 36.8 |
2 | 28 | 29.5 |
3 | 20 | 21.1 |
≥ 4 | 12 | 12.6 |
Nº of positive SN (Mic + MAC) | ||
0 | 4 | 4.2 |
1 | 65 | 68.4 |
2 | 20 | 21.1 |
3 | 4 | 4.2 |
≥ 4 | 2 | 2.1 |
Size of the SLN metastasis | ||
ITC (i+) | 0 | 0 |
Micrometastasis (Mic) | 0 | 0 |
Macrometastasis (MAC) | 95 | 100 |
Number of positive SLN | ||
0 | 55 | 57.9 |
1 | 21 | 22.1 |
2-3 | 11 | 11.6 |
1-3 | 32 | 33.7 |
≥ 4 | 8 | 8.4 |
Adjuvant treatments | ||
Radiotherapy | 75/90 | 82.4 |
Chemotherapy | 72/90 | 80 |
Hormonotherapy | 79/90 | 87.7 |
Immunotherapy | 4/92 | 4.3 |
Table 2 Univariate analysis of 95 patients with presence of sentinel lymph nodes with macrometastases
No additional metastatic lymph nodes | Additional metastatic lymph nodes | P value | |
Age | |||
< 40 | 66% | 44% | 0.04 |
≥ 40 | 32.6% | 67.4% | |
Hormonal status | |||
Premenopausal | 70% | 30% | NS |
Postmenopausal | 60% | 40% | |
T stage | |||
T1 | 75.8% | 24.2% | < 0.05 |
T2 | 47% | 53% | |
T3 | 0 | 100% | |
Tumor size | |||
≤ 15 mm | 85% | 15% | < 0.05 |
> 15 mm | 49% | 51% | |
Histologic type | |||
Ductal carcinoma | 67.1% | 32.9% | NS |
Lobular carcinoma | 47% | 53% | |
Grade | |||
I + II | 68.6% | 31.4% | NS |
III | 54% | 46% | |
Molecular subtype | |||
Luminal A/B | 65.6% | 34.4% | < 0.05 |
Basal | 22.2% | 77.8% | |
HER2 | 100% | 0 | |
LVI | |||
Present | 66.7% | 33.3% | NS |
Absent | 61.5% | 38.5% | |
Number of positive SLN | |||
1 | 69.6% | 31.4% | < 0.05 |
≥ 2 | 43.7% | 66.3% | |
ACOSOG Z0011 criteria | |||
≤ 2 SLN+ | 68.5% | 31.5% | < 0.05 |
> 2 SLN+ | 16% | 84% |
Table 3 Multivariate analysis of 95 patients with sentinel lymph nodes with macrometastases
P value | Odds ratio | ||
Tumor size | ≤ 15 mm vs > 15 mm | 0.002 | 2.004 |
Number of metastatic SLN | 1 vs > 1 | 0.021 | 2.573 |
ACOSOG Z0011 criteria | ≤ 2 SLN+ vs > 2 SLN+ | 0.045 | 10.195 |
Table 4 Univariate analysis of variables related to the presence of additional disease on completion axillary lymph node dissection in the group of 79 cases with presence of only one macrometastatic sentinel lymph nodes
Additional metastatic lymph nodes, n = 79 | |
Age | |
< 40 | 50% |
≥ 40 | 28% |
≤ 15 mm | 85% |
> 15 mm | 49% |
Histologic type | |
Ductal carcinoma | 28% |
Lobular carcinoma | 50% |
Mucinous | 0 |
Tumor size | |
≤ 10 mm | 7% |
11-15 mm | 10% |
16-20 mm | 42% |
> 20 mm | 47% |
Grade | |
DCIS | 0 |
I | 18% |
II | 31% |
III | 45% |
Molecular subtype | |
Luminal A/B | 28% |
Basal | 55% |
HER2 | 0 |
- Citation: Herrero M, Ciérvide R, Calle-Purón ME, Valero J, Buelga P, Rodriguez-Bertos I, Benassi L, Montero A. Macrometastasis at selective lymph node biopsy: A practical going-for-the-one clinical scoring system to personalize decision making. World J Clin Oncol 2021; 12(8): 675-687
- URL: https://www.wjgnet.com/2218-4333/full/v12/i8/675.htm
- DOI: https://dx.doi.org/10.5306/wjco.v12.i8.675